Organization
Akershus University Hospital (Ahus)
8 abstracts
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.Org: Örebro University Hospital, Santo Stefano Hospital, General Hospital of Patras St. Andrews, Akershus University Hospital (Ahus), Papageorgiou General Hospital,
Abstract
Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.Org: Akershus University Hospital (Ahus), Lorenskog, Sørlandet Hospital, Kristiansand, St.Olav's University Hospital,
Abstract
Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2).Org: Huntsman Cancer Institute, University of Utah, Medical Oncology Group, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology,
Abstract
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, Australian Catholic University, Institut Gustave Roussy, University of Paris-Saclay,
Abstract
IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway.Org: University of Oslo, Division of Cancer Medicine, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Institute of Clinical Medicine, Oslo Universitetssykehus, Oslo, Norway,
Abstract
Circulating levels of the pro-inflammatory monomeric isoform of C-reactive protein (mCRP) correlate with inflammatory markers in patients with stage II-III colon cancer.Org: Akershus University Hospital (Ahus), Sørlandet Hospital, University of Louisville,